$PHIO
Phio Pharmaceuticals Corp

2022 Q3 Form 10-Q Financial Statement

#000168316822005565 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.063M $1.217M $1.054M
YoY Change 14.06% 19.2% 3.33%
% of Gross Profit
Research & Development $2.508M $1.304M $1.586M
YoY Change -10.65% -16.36% -39.47%
% of Gross Profit
Depreciation & Amortization $15.00K $19.00K $22.00K
YoY Change -21.05% 18.75% 10.0%
% of Gross Profit
Operating Expenses $3.571M $2.521M $2.640M
YoY Change -4.49% -6.07% -27.47%
Operating Profit -$3.571M -$2.521M -$2.640M
YoY Change -4.49% -6.07%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$5.000K -$10.00K -$2.000K
YoY Change 66.67% 233.33%
Pretax Income -$3.576M -$2.531M -$2.642M
YoY Change -4.44% -5.81% -22.52%
Income Tax
% Of Pretax Income
Net Earnings -$3.576M -$2.531M -$2.642M
YoY Change -4.44% -5.81% -22.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.26 -$0.19 -$2.34
Diluted Earnings Per Share -$0.26 -$0.19 -$194.8K
COMMON SHARES
Basic Shares Outstanding 13.66M shares 13.66M shares 1.130M shares
Diluted Shares Outstanding 13.66M shares 13.66M shares 1.130M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.48M $18.02M $20.46M
YoY Change -45.4% -38.76% -37.43%
Cash & Equivalents $14.53M $18.07M $20.46M
Short-Term Investments
Other Short-Term Assets $893.0K $1.668M $1.208M
YoY Change -3.04% -3.58% 91.75%
Inventory
Prepaid Expenses $843.0K $1.618M
Receivables
Other Receivables
Total Short-Term Assets $15.38M $19.69M $21.67M
YoY Change -43.98% -36.81% -34.97%
LONG-TERM ASSETS
Property, Plant & Equipment $198.0K $206.0K $468.0K
YoY Change -57.51% -57.44% -10.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $24.00K $27.00K $27.00K
YoY Change -11.11% 50.0% 35.0%
Total Long-Term Assets $414.0K $456.0K $495.0K
YoY Change -16.02% -9.16% -8.33%
TOTAL ASSETS
Total Short-Term Assets $15.38M $19.69M $21.67M
Total Long-Term Assets $414.0K $456.0K $495.0K
Total Assets $15.79M $20.14M $22.16M
YoY Change -43.49% -36.37% -34.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $543.0K $1.148M $329.0K
YoY Change 68.63% 229.89% -46.94%
Accrued Expenses $1.519M $1.759M $2.244M
YoY Change -30.1% -21.12% 42.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.194M $3.037M $2.573M
YoY Change -12.06% 17.8% 17.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $70.00K $104.0K $138.0K
YoY Change -65.35% -55.56% -48.89%
Total Long-Term Liabilities $70.00K $104.0K $138.0K
YoY Change -65.35% -55.56% -48.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.194M $3.037M $2.573M
Total Long-Term Liabilities $70.00K $104.0K $138.0K
Total Liabilities $2.264M $3.141M $2.711M
YoY Change -16.05% 11.7% 10.2%
SHAREHOLDERS EQUITY
Retained Earnings -$125.6M -$122.1M
YoY Change
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.53M $17.00M $19.45M
YoY Change
Total Liabilities & Shareholders Equity $15.79M $20.14M $22.16M
YoY Change -43.49% -36.37% -34.55%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.576M -$2.531M -$2.642M
YoY Change -4.44% -5.81% -22.45%
Depreciation, Depletion And Amortization $15.00K $19.00K $22.00K
YoY Change -21.05% 18.75% 10.0%
Cash From Operating Activities -$3.526M -$2.429M -$3.469M
YoY Change 23.03% -30.42% 14.49%
INVESTING ACTIVITIES
Capital Expenditures -$7.000K -$10.00K -$104.0K
YoY Change -76.67% -9.09% 940.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$7.000K -$10.00K -$104.0K
YoY Change -76.67% -9.09% 940.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.000K 0.000 -25.00K
YoY Change -100.0% -100.12%
NET CHANGE
Cash From Operating Activities -3.526M -2.429M -3.469M
Cash From Investing Activities -7.000K -10.00K -104.0K
Cash From Financing Activities -3.000K 0.000 -25.00K
Net Change In Cash -3.536M -2.439M -3.598M
YoY Change 22.1% -25.39% -119.5%
FREE CASH FLOW
Cash From Operating Activities -$3.526M -$2.429M -$3.469M
Capital Expenditures -$7.000K -$10.00K -$104.0K
Free Cash Flow -$3.519M -$2.419M -$3.365M
YoY Change 24.08% -30.49% 11.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Address Line1
EntityAddressAddressLine1
257 Simarano Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 101
dei Entity Address City Or Town
EntityAddressCityOrTown
Marlborough
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Central Index Key
EntityCentralIndexKey
0001533040
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
usd
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
usd
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36304
dei Entity Registrant Name
EntityRegistrantName
Phio Pharmaceuticals Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-3215903
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01752
dei City Area Code
CityAreaCode
508
dei Local Phone Number
LocalPhoneNumber
767-3861
dei Security12b Title
Security12bTitle
Common Stock, par value, $0.0001 per share
dei Trading Symbol
TradingSymbol
PHIO
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000 usd
CY2022Q2 us-gaap Assets
Assets
20144000 usd
CY2021Q4 us-gaap Assets
Assets
25170000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1148000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
283000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1759000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2660000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
130000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
125000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3037000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3068000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
104000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
170000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
3141000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
3238000 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13658722 shares
CY2022Q2 us-gaap Cash
Cash
18020000 usd
CY2021Q4 us-gaap Cash
Cash
24057000 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
50000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
50000 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1618000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
620000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
19688000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
24727000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
223000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
283000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
206000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
133000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13658722 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13658722 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13534996 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13534996 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139075000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
138831000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122073000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116900000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
17003000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21932000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20144000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25170000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1304000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1559000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2890000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3988000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1217000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1125000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2271000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2334000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
2521000 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
2684000 usd
us-gaap Operating Expenses
OperatingExpenses
5161000 usd
us-gaap Operating Expenses
OperatingExpenses
6322000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2521000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2684000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5161000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6322000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
228000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2531000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2687000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5173000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6094000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13658722 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13534389 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13611687 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12115276 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13658722 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13534389 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13611687 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12115276 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21932000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
25000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
186000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2642000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
19451000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
83000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2531000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
17003000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
13017000 usd
CY2021Q1 phio Issuance Of Common Stock Prefunded Warrants And Warrants In Connection With Private Placement Net Of Offering Costs
IssuanceOfCommonStockPrefundedWarrantsAndWarrantsInConnectionWithPrivatePlacementNetOfOfferingCosts
12669000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6908000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2146000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3407000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
31400000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
132000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2687000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
28845000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5173000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6094000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
60000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
58000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
269000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
199000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
233000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
998000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
810000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
865000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-380000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-901000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
760000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-61000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-57000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5898000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6521000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
114000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-114000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
0 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
19577000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2146000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
25000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
-0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21723000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6037000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
15181000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24107000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14294000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18070000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29475000 usd
CY2022Q2 us-gaap Cash
Cash
18020000 usd
CY2021Q2 us-gaap Cash
Cash
29425000 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
50000 usd
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
50000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18070000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29475000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_841_eus-gaap--NatureOfOperations_zxXz8mhTMUNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86B_zYmE26EcIsbl">Nature of Operations</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phio Pharmaceuticals Corp. (“<b>Phio</b>,” “<b>we</b>,” “<b>our</b>” or the “<b>Company</b>”) strives to address the biggest challenges in immuno-oncology by working to create new pathways to a cancer-free future for patients. We are developing therapeutics that leverage our INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient’s immune system while weakening tumor defense mechanisms. With our INTASYL self-delivering RNAi technology, we aim to bring the benefits of RNA therapeutics into cancer care where other modalities may fall short.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company continues to respond to and monitor the ongoing coronavirus pandemic. The Company’s corporate headquarters and research facility have seen limited impact and, during the three and six months ended June 30, 2022, continued to operate with safety measures in place for the health and well-being of its employees, such as working remotely and flexible scheduling, in accordance with guidance from federal, state and local authorities. The Company believes that the coronavirus pandemic has not had a significant impact on its financial condition and results of operations for the three and six months ended June 30, 2022. However, the extent to which the coronavirus pandemic may materially impact our financial results and operations will depend on a number of factors, including the availability of supplies and services we rely on, the ability to enroll subjects in our clinical trials and the duration of the coronavirus pandemic, which remain difficult to predict and are highly uncertain.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9000 usd
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0470 pure
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
33000 usd
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
33000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
66000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
66000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zovej0PQed12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_868_zvhSK9RQrzrh">Uses of Estimates in Preparation of Financial Statements</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets. On an ongoing basis, we evaluate our estimates and base our estimates on historical experience and other relevant assumptions that we believe are reasonable under the circumstances, including as a result of new information that may emerge concerning the coronavirus pandemic and the ongoing conflict between Russia and Ukraine. Actual results could differ materially from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p>
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
34000 usd
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
33000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
67000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
65000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
68000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
140000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
35000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
243000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
223000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
283000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
130000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
125000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
104000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
170000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
234000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
295000 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0470 pure
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
234000 usd
CY2022Q2 phio Warrants Exercised Shares
WarrantsExercisedShares
0 shares
CY2021Q2 phio Warrants Exercised Shares
WarrantsExercisedShares
0 shares
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2146000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7233143 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6905181 shares
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
83000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
132000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
269000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
199000 usd
CY2022Q2 us-gaap Contractual Obligation
ContractualObligation
4000000 usd

Files In Submission

Name View Source Status
0001683168-22-005565-index-headers.html Edgar Link pending
0001683168-22-005565-index.html Edgar Link pending
0001683168-22-005565.txt Edgar Link pending
0001683168-22-005565-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
phio-20220630.xsd Edgar Link pending
phio_ex3101.htm Edgar Link pending
phio_ex3201.htm Edgar Link pending
phio_i10q-063022.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
phio-20220630_cal.xml Edgar Link unprocessable
phio-20220630_pre.xml Edgar Link unprocessable
phio-20220630_lab.xml Edgar Link unprocessable
phio-20220630_def.xml Edgar Link unprocessable
phio_i10q-063022_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable